elapegademase (Revcovi)
Jump to navigation
Jump to search
Indications
- treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric & adult patients
Dosage
Laboratory
- adjust dose gradually down to maintain trough ADA activity >30 mmol/hr/L, trough dAXP level <0.02 mmol/L, &/or to maintain adequate immune reconstitution based on clinical assessment
Mechanism of action
- PEGylated recombinant adenosine deaminase
More general terms
References
- ↑ RxNorm
- ↑ PubChem: 121488177
- ↑ FDA Approves Elapegademase for Treatment of ADA-SCID in Pediatric and Adult Patients Rare Disease Report. Oct 5, 2018 https://www.raredr.com/news/fda-approves-elapegademase-treatment-adascid-in-pediatric-adult-patients
- ↑ elapegademase (Rx) Medscape https://reference.medscape.com/drug/revcovi-elapegademase-1000300